Toprol-XL Eyed As Precedent For Brilinta Labeling On U.S. Efficacy Data

Labeling for AstraZeneca's antiplatelet agent Brilinta could follow in the mold of the company's own beta-blocker Toprol-XL in reflecting dissimilar efficacy reported for U.S. patients compared with those in the rest of the world